The number of patients who require maintenance on anticoagulation therapy (warfarin/Coumadin ®) for minimizing risk of cardiovascular events like stroke or thromboembolism is increasing.

In the first large trial of its kind, the anti-clotting medication rivaroxaban did not lower the risk of cognitive decline ...

Study Selection: This includes studies concerning the diagnosis and incidence of PE and DVT, efficacy of anticoagulants in preventing complications, risks of anticoagulant therapy, and the costs ...

Maxim Group analyst Naz Rahman has reiterated their bullish stance on TLPH stock, giving a Buy rating on November 14. Naz Rahman has given his ...

"The results we reviewed here have significant implications for optimizing anticoagulation therapy and improving patient outcomes in clinical practice," said Behnood Bikdeli, MD, MS, of the Brigham's ...

Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone is linked to reduced ischemic stroke risk in select patients with nonvalvular AF.

which could address significant unmet needs in the anticoagulation therapy market. Trending Articles AcelRx Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

It was safe to start direct oral anticoagulant (DOAC) therapy without delay after acute ischemic stroke in people with atrial ...

Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla., Oct. 23, 2024 /PRNewswire/ -- Cadrenal ...